MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Oxidative stress"

  • MDS Virtual Congress 2020

    Non-mercaptalbumin as a potential biomarker of oxidative stress in Parkinson’s and PARK2 disease

    S. Ueno, T. Hatano, A. Okuzumi, S. Saiki, Y. Oji, A. Mori, T. Koinuma, M. Fujimaki, H. Takeshige-Amano, A. Kondo, N. Yoshikawa, T. Nojiri, M. Kurano, K. Yasukawa, Y. Yatomi, H. Ikeda, N. Hattori (Tokyo, Japan)

    Objective: To elucidate the oxidized albumin ratio, which is the redox ratio of human non-mercaptalbumin (HNA) to serum albumin (%HNA), as a biomarker in parkinsonism.…
  • MDS Virtual Congress 2020

    Neuroprotective and neuromodulatory properties of Olea purpurea leaf extract in MPTP intoxicated Parkinsonian rat model

    A. Singh, T. Yadav, A. Pandey (Allahabad, India)

    Objective: This study aimed to isolate and characterize Olea purpurea leaf extract, and its neuroprotective effect in MPTP induced parkinsonian rat model. Background: Parkinson's disease (PD), also…
  • MDS Virtual Congress 2020

    The relationship between serum uric acid and depression in patients with essential tremor

    Z. Muruzheva, I. Ivleva, M. Karpenko (Saint-Petersburg, Russian Federation)

    Objective: To identity a correlation between serum indicators oxidative stress (uric acid, malondialdehyde and ceruloplasmin) and clinical symptoms in patients with ET. Background: Essential tremor…
  • 2019 International Congress

    Disease-in-a-dish: drug discovery using patient-derived stem cells in Hereditary Spastic Paraplegia

    Y. Fan, G. Wali, R. Sutharsan, C. Sue, A. Mackay-Sim (Sydney, Australia)

    Objective: Identify a drug treatment for Hereditary Spastic Paraplegia (HSP) using patient-derived stem cell models Background: HSP is a neurological disorder characterised by axonal degeneration…
  • 2019 International Congress

    Role of microRNA-153 and -223 in Parkinson disease

    M. Cressatti, W. Song, L. Jawura, J. Galindez, O. Canie, A. Velly, M. Gornitsky, H. Schipper (Montreal, QC, Canada)

    Objective: To assess the therapeutic and diagnostic potential of microRNA (miR)-153 and miR-223 in mice and humans with parkinsonism. Background: Dysregulated miRNAs play a major…
  • 2019 International Congress

    Gender-specific effects of uric acid on the development of freezing of gait in Parkinson’s disease

    JH. Jung, SJ. Chung, YH. Sohn, PH. Lee (Seoul, Republic of Korea)

    Objective: To investigate whether serum uric acid level is gender-specifically associated with the development of freezing of gait (FOG) in patients with de novo Parkinson’s…
  • 2019 International Congress

    Beneficial and protective effects of Terminalia chebula in a murine model of Parkinson’s disease

    A. Kumar, S. Farhat (New Delhi, India)

    Objective: Present study was designed to investigate whether Terminalia chebula (TC) extract would prevent 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)  induced neurotoxicity in male Wistar rats. Background: Parkinson's disease (PD)…
  • 2019 International Congress

    High-throughput screening using a Drosophila model of Parkinson’s disease

    FJ. Lopez, C. Solana, E. Masia, MJ. Vicent, N. Paricio (Valencia, Spain)

    Objective: To identify potential therapeutic compounds for Parkinson’s disease (PD) treatment by combining a phenotype-based high-throughput screening assay in PD model flies with a validation…
  • 2019 International Congress

    Nrf2 pathway in patients with Parkinson’s disease

    T. Schirinzi, S. Petrillo, G. Di Lazzaro, N. Mercuri, E. Bertini, F. Piemonte, A. Pisani (Rome, Italy)

    Objective: To demonstrate the activation of Nuclear factor erythroid-2-related factor 2 (Nrf2) pathway in PD patients. Background: Experimental data indicated the critical involvement of Nrf2…
  • 2019 International Congress

    Serum non-mercaptalbumin as a potential biomarker in Parkinson’s disease and related disorders

    S. Ueno, T. Hatano, A. Okuzumi, S. Saiki, Y. Oji, A. Mori, T. Koinuma, M. Fujimaki, H. Takeshige-Amano, K. Yasukawa, Y. Yatomi, H. Ikeda, N. Hattori (Tokyo, Japan)

    Objective: To investigate the oxidized albumin ratio, which is the redox ratio of human non-mercaptalbumin (HNA) to serum albumin (HSA) (%HNA), as a biomarker in…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 8
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Life expectancy with and without Parkinson’s disease in the general population
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley